Taysha Gene Therapies To Discontinue Development Of Its TSHA-120 Program In Evaluation For Treatment Of Giant Axonal Neuropathy
Portfolio Pulse from Benzinga Newsdesk
Taysha Gene Therapies has decided to discontinue the development of its TSHA-120 program for the treatment of Giant Axonal Neuropathy (GAN) following feedback from the U.S. FDA. The decision was made due to challenges with study design feasibility for potential Biologics License Application (BLA) submission. Additionally, Astellas Gene Therapies has chosen not to exercise its option to obtain an exclusive license to TSHA-120 under the Option Agreement.
September 19, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Taysha's decision to discontinue the TSHA-120 program could negatively impact the company's stock in the short term as it indicates a setback in their product pipeline.
The discontinuation of a significant program like TSHA-120 indicates a setback in Taysha's product development pipeline. This could lead to a negative investor sentiment, potentially causing a short-term drop in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100